When the Nation’s Top Drug Safety Official Says Johnson & Johnson “Misled the FDA for Over the Last Half Century” — What That Means for Your Family in Los Angeles
If you are reading this, someone you love may have used Johnson & Johnson talc products for years — for feminine hygiene, for the daily routine that felt as safe as breathing — and then received an ovarian cancer diagnosis that seemed to come from nowhere. You may have buried her already. You may be sitting beside her now. And you may have just learned that a former Commissioner of the FDA — the person who once ran the agency charged with protecting Americans from exactly this kind of harm — walked into a Los Angeles courtroom and told a jury that one of the largest healthcare companies on earth spent fifty years lying to his agency about what was in its powder.
We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic tort and wrongful death cases, and we are writing to you as the senior trial attorney who reads internal corporate documents for a living and knows what they mean when a company’s own handwriting says “Do Not Use This Report: Replaced by Another Version.” That is not a footnote. That is a confession on paper. And it is now sitting in front of a Los Angeles jury because three women are dead and their families refused to let the story stay buried.
This page is not a news article. It is the full legal, medical, and financial map of what a talc-related ovarian cancer case looks like in California — the law that governs it, the evidence that wins it, the money it is worth, the deadlines that can kill it, and the defense playbook the other side is already running against you. Everything here is written to protect you, whether you ever call us or not. But if you do call, the consultation is free, and we don’t get paid unless we win your case.
What Happened in This Los Angeles Courtroom — and Why It Matters to Your Family
A jury in Los Angeles County is hearing claims that Johnson & Johnson’s talc-based products — products used by millions of American women for feminine hygiene over decades — caused three women’s fatal ovarian cancer. The expert witness who walked the jury through the company’s internal history was not a hired academic. He was Dr. David A. Kessler, who served as Commissioner of the U.S. Food and Drug Administration from 1990 through 1997 — the nation’s top drug and cosmetic safety official. His testimony, given under oath and subject to cross-examination, described a pattern of corporate conduct spanning from the 1970s through at least 2016.
“Misled the FDA for over the last half century.”
— Dr. David A. Kessler, former FDA Commissioner, testifying as a plaintiff expert witness in the Los Angeles talc ovarian cancer trial.
That sentence — spoken by the man who once ran the agency being deceived — is the spine of this case and of every talc cancer claim that follows it. It is not a lawyer’s accusation. It is not a newspaper headline. It is the sworn testimony of the person who would have been in the best position in the country to know whether a company was telling the FDA the truth about what was in its product.
What Dr. Kessler described, document by document, was not a mistake. It was a fifty-year system of concealment.
The Documentary Evidence: Altered Reports, Suppressed Tests, and a Handwritten Instruction to Replace the Truth
The evidence Dr. Kessler walked the jury through is not circumstantial. It is internal J&J paperwork — memos, test reports, and correspondence that the company created and that now exists as trial exhibits. Here is what those documents show, as described in the testimony:
The McCrone Report Substitution. In the 1970s, J&J retained a testing consultant called McCrone & Associates to analyze its talc for asbestos contamination. Tests found what Kessler described as “alarming asbestos levels.” But the report containing those findings was not the report that reached the FDA. A handwritten note on the original report read: “Do Not Use This Report: Replaced by Another Version.” The replacement version substantially reduced the reported tremolite asbestos amounts. Tremolite is one of the forms of asbestos — a recognized human carcinogen. Reducing the reported number meant the FDA was told the problem was smaller than the company’s own testing showed.
The 1976 Executive Memo. A J&J executive wrote an internal memo describing an FDA proposal to test talc for asbestos as “disturbing.” The reason it was disturbing, in the executive’s own words, was that the proposed test was “ultra sophisticated” and that “chances are that this FDA proposal will open up new problem areas with asbestos and talc minerals.” In plain English: the company was not worried that the FDA would find nothing. It was worried that the FDA would find something.
The J4-1 Test. J&J convinced the FDA to accept a testing method called the J4-1 test rather than having the agency conduct its own testing. Dr. Kessler testified that the J4-1 test was not accurate enough to be safe: it could not detect chrysotile asbestos — the type most commonly associated with mesothelioma — and it could not detect any asbestos below a concentration of 0.5%. At that threshold, the test could miss millions of carcinogenic fibers. The FDA opted out of testing talc in the 1970s because it trusted the company’s assurances that self-testing was sufficient.
The Chemical Treatment. Internal documents showed that upon detecting asbestos in its mined talc, J&J began using a chemical method to reduce asbestos levels — but never informed the FDA that it was doing so. The agency that was relying on the company’s self-reported safety data did not know the company was altering the raw material.
The 2016 Letter. In 2016 — decades after the 1970s memos and altered reports — J&J sent a letter to the FDA asserting that “no asbestos-forming structures have ever been found” in its talc. Dr. Kessler testified that this statement was untrue. If he is right, the company was still making false representations to the federal government about the safety of its product as recently as 2016 — within the statute of limitations window for many women diagnosed in the years that followed.
The Cross-Examination Exchange. Under cross-examination, when defense counsel suggested that tremolite found in old documents might not be the asbestos-forming type that causes mesothelioma, Dr. Kessler pushed back directly: “So, here we go, you’re spinning the definition of asbestos. That’s what’s gone on for decades.” He continued: “If it’s a fiber, if it says tremolite fiber, if it’s long and can do harm, causing mesothelioma. That’s the biological activity … this isn’t just about geology, this is about biology and medicine.”
That exchange captures the entire battlefield. The defense argument is about mineralogy — whether the fibers meet a technical geological definition. The plaintiff’s argument is about biology — whether the fibers are the kind that reach human tissue and stay there long enough to cause cancer. Dr. Kessler’s point is that the company spent decades narrowing the definition to avoid finding what the body already knows is there.
What This Means If Your Loved One Used Talc Products and Was Diagnosed with Ovarian Cancer
The trial in Los Angeles involves three women who died of ovarian cancer after using J&J talc products for feminine hygiene. But the evidence being presented in that courtroom — the altered McCrone reports, the 1976 executive memo, the J4-1 testing deficiencies, the chemical treatment concealment, the 2016 FDA letter — is not specific to those three women. It is evidence of corporate conduct that affected every consumer who used those products during the decades the concealment was ongoing.
If your mother, wife, sister, daughter, or partner used J&J talc products — including Johnson’s Baby Powder or Shower to Shower — for perineal or feminine hygiene and was later diagnosed with ovarian cancer, the evidence being presented in this Los Angeles trial may be directly relevant to your family’s case. The question is not whether the company’s conduct was wrong. A former FDA Commissioner has now said under oath that it was. The question is whether that conduct caused your loved one’s cancer — and whether you can prove it before the evidence and the legal deadlines run out.
That is what the rest of this page is about.
California Product Liability Law: The Framework That Governs Your Case
California is one of the strongest states in the country for a person injured by a dangerous product. The reason is a legal doctrine called strict products liability, which California adopted in a landmark case called Greenman v. Yuba Power Products — a decision that changed American tort law by holding that a manufacturer is responsible for injuries caused by its defective product without the injured person having to prove the company was negligent.
In plain English: you do not have to prove Johnson & Johnson was careless. You have to prove its product was defective and that the defect caused your loved one’s cancer. In a talc case, that means proving two things: that the talc contained asbestos or was unreasonably dangerous for its foreseeable use, and that the exposure caused the ovarian cancer.
Design Defect. California applies two tests for design defect: the consumer expectation test (did the product perform as safely as an ordinary consumer would expect?) and the risk-benefit test (did the dangers of the design outweigh its benefits, and was there a safer alternative?). A talc product contaminated with asbestos — sold for use on the most sensitive parts of a woman’s body — fails both tests. No consumer expects a baby powder to contain a known carcinogen. And no benefit of talc over cornstarch (the safer alternative the industry ultimately moved toward) outweighs the risk of fatal cancer.
Failure to Warn. J&J failed to warn consumers or regulators of the presence of asbestos in its talc and the associated cancer risk, despite decades of internal knowledge. The 2016 letter to the FDA asserting no asbestos-forming structures had been found — which Dr. Kessler called false — is direct evidence of both the failure to warn and active misrepresentation. A failure-to-warn claim in California does not require proof of negligence; it requires proof that the product was sold without adequate warnings about a known danger and that the absence of those warnings caused the injury.
Fraudulent Concealment. This is where the altered McCrone reports and the handwritten “Do Not Use This Report” note become more than historical artifacts. California law recognizes fraudulent concealment as a separate cause of action when a defendant actively hides a material fact it had a duty to disclose. The elements are: the defendant concealed or suppressed a material fact, the defendant knew the fact was true, the defendant had a duty to disclose it, the plaintiff was unaware of the fact and would have acted differently had she known, and the plaintiff was damaged as a result. The decades of document alteration, test-result substitution, and opposition to FDA testing — described by the former FDA Commissioner as misleading the agency “for over the last half century” — is the strongest fraudulent concealment fact pattern you can build.
Fraudulent Misrepresentation. Separate from concealment, California law recognizes claims for affirmative false representations. The 2016 FDA letter is the clearest example: an affirmative statement to a federal regulator that Kessler testified was untrue. If the company told the FDA “no asbestos-forming structures have ever been found” while its own internal documents from the 1970s showed exactly that, the gap between what it said publicly and what it knew privately is the fraud.
Punitive Damages. This is where California law becomes a weapon. California Civil Code § 3294 permits punitive damages — damages designed to punish the defendant and deter future misconduct — upon a showing by clear and convincing evidence of oppression, fraud, or malice. The standard is “despicable conduct carried on by the defendant with a willful and conscious disregard for the safety of others.”
The trial testimony in this Los Angeles case — report alteration, a handwritten instruction to suppress unfavorable findings, internal executive memos opposing regulatory testing, chemical treatment of asbestos-contaminated ore without informing the FDA, and a 2016 letter a former FDA Commissioner called false — is the clearest and most convincing evidence of fraud and malice that a jury can receive. The concealment spanned from the 1970s through 2016 and beyond. The number of affected consumers is nationwide. A jury that hears this evidence and finds for the plaintiff on liability will face the question of punitive damages with a documentary record that makes the answer nearly inescapable.
No Damage Caps. California does not impose statutory damage caps on product liability or toxic tort claims against corporate defendants. The caps that exist in California under MICRA — the Medical Injury Compensation Reform Act — apply exclusively to medical negligence actions, not to product liability cases. There is no statutory ceiling on what a Los Angeles jury can award in a talc cancer case — not on compensatory damages, and not on punitive damages.
Comparative Fault. California follows pure comparative negligence, which means a plaintiff’s own share of fault reduces her recovery but never bars it entirely. In talc cancer cases, comparative fault is typically minimal or absent because consumers had no knowledge of the asbestos contamination — the entire premise of the fraudulent concealment claim is that the company hid the danger. A jury is unlikely to reduce a verdict because a woman used a product the manufacturer told her was safe.
The Statute of Limitations: When the Clock Starts, and Why It May Not Have Started When You Think
This is the question that kills more toxic tort cases than any defense argument: how long do you have to file, and when does the clock begin?
California’s statute of limitations for personal injury and wrongful death is generally two years. Under California’s Code of Civil Procedure, an action for injury to or the death of an individual caused by the wrongful act or neglect of another must be brought within two years. But in toxic exposure cases — where the disease can take decades to develop after the exposure — California applies what is called the discovery rule.
The discovery rule means the clock does not start ticking on the date of exposure. It starts when the plaintiff discovered, or by reasonable diligence should have discovered, both the injury AND its causal connection to the product. For a woman who used talc products in the 1980s and 1990s but was not diagnosed with ovarian cancer until years later — and who may not have known until recently that talc could be contaminated with asbestos or linked to ovarian cancer — the clock may have started far more recently than the exposure date.
Wrongful Death Deadline. If your loved one has already passed away, the wrongful death statute of limitations generally runs two years from the date of death — not from the date of diagnosis or the date of exposure. This deadline can arrive faster than families expect, especially when the grieving process consumes the first year.
The Survival Action. California also permits a survival action — a claim brought by the estate for the decedent’s pre-death pain and suffering, medical expenses, and lost earnings. The survival action’s statute of limitations is tied to the decedent’s own claim, which means the discovery rule applies to it as well. But if the decedent never filed a claim during her lifetime, the survival action’s viability depends on whether her claim was still viable when she died.
What This Means for You. Do not assume it is too late. Do not assume the clock started years ago. And do not assume you have plenty of time. The discovery rule is your friend, but it is also a legal argument that must be made — it is not automatic. The only way to know whether your claim is still alive is to have an experienced California toxic tort attorney evaluate the specific timeline of your loved one’s product use, diagnosis, and discovery of the causal connection. Confirm the current California limitations deadline with experienced counsel immediately.
The Medicine: How Talc Exposure Is Linked to Ovarian Cancer
Ovarian cancer is not a single disease — it is a category of malignancies that arise from the ovaries and related tissues. It is among the most lethal of gynecologic cancers because it is often diagnosed at a late stage, after the cancer has spread beyond the ovary. The symptoms — bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, urinary urgency or frequency — are vague enough that they are frequently dismissed or attributed to other conditions until the disease is advanced.
The Talc-to-Ovarian Cancer Theory. The plaintiff’s theory in talc ovarian cancer cases is biologically specific: when talc powder is used for perineal or feminine hygiene, particles migrate from the external genital area up through the reproductive tract — through the vagina, through the cervix, through the uterus, and into the fallopian tubes and ovaries. Talc particles, and any asbestos fibers contaminating the talc, reach the ovarian tissue and lodge there. The body cannot fully clear them. The particles cause chronic inflammation — a persistent immune response that, over years and decades, creates a cellular environment in which malignancy can develop. This inflammation-driven carcinogenesis pathway is biologically plausible and is supported by epidemiological studies showing an association between perineal talc use and increased ovarian cancer risk.
The Asbestos Amplifier. If the talc was contaminated with asbestos — as the internal J&J documents described by Dr. Kessler suggest it was — the carcinogenic potential is dramatically higher. Asbestos is classified by the International Agency for Research on Cancer as a Group 1 known human carcinogen. There is no scientific debate about whether asbestos causes cancer. The debate in talc cases is about whether the asbestos contamination was present, at what levels, and whether it reached the ovarian tissue. The altered McCrone reports — which reduced reported tremolite amounts before submission to the FDA — go directly to the question of whether the company knew the contamination was worse than it disclosed.
The Disease Progression. The damages analysis in these cases is driven by what ovarian cancer does to a human body over time. Advanced ovarian cancer involves progressive abdominal pain as tumors grow and press on surrounding organs. Ascites — fluid accumulation in the abdomen — can cause visible distension, difficulty breathing, and severe discomfort. Bowel obstruction can occur when tumors compress the intestine, leading to nausea, vomiting, and inability to eat. Cachexia — the wasting syndrome associated with advanced cancer — strips the body of muscle and fat, leaving the patient weakened and unable to fight. Treatment involves surgery (debulking to remove as much tumor as possible) and chemotherapy (typically platinum-based drugs like carboplatin and paclitaxel), which cause their own suffering: nausea, hair loss, neuropathy, fatigue, immunosuppression. If the cancer recurs — which it frequently does — the prognosis worsens and the treatment cycles repeat.
This is what the survival action captures: the months or years of physical suffering your loved one endured between diagnosis and death. It is not a number a defense lawyer can shrink by calling the science uncertain. The suffering is documented in the medical records, in the chemotherapy logs, in the surgical reports, in the hospice notes.
The Scientific Debate — Honest. The defense in talc cases contests the causal link between perineal talc use and ovarian cancer. They point to other risk factors (family history, BRCA mutations, age, nulliparity, hormone therapy) and argue that the plaintiff cannot prove talc caused this particular cancer rather than some other factor. This is a real defense — not a frivolous one — and it is why expert witness selection is critical. The plaintiff’s case requires board-certified gynecologic oncologists who can explain the inflammation pathway, epidemiologists who can address the association studies, mineralogists who can characterize the asbestos fibers found in the talc, and forensic document examiners who can authenticate the altered reports. The asbestos contamination evidence — proven by the company’s own internal documents — is the counter to the “idiopathic cancer” defense. If the talc contained a known carcinogen that the company knew about and concealed, the defense’s argument that the cancer “came from nowhere” collapses.
The Defendant: Johnson & Johnson’s Corporate Structure and the Bankruptcy Shell Game
Johnson & Johnson is not a single entity. It is a corporate family designed — like all large corporate families — to separate operations, assets, and liability into different legal containers. Understanding this structure is not optional. It is the difference between suing the entity with money and suing an empty shell.
The Corporate Family. Johnson & Johnson (the parent) historically separated its operations into three divisions: consumer health products, pharmaceuticals, and medical devices. The entity that manufactured and marketed the talc-based products at issue — Johnson’s Baby Powder and Shower to Shower — was Johnson & Johnson Consumer Inc., known as JJCI. In 2023, J&J spun off its consumer health division into a separate publicly traded company called Kenvue Inc., which now owns brands like Band-Aid, Tylenol, and Listerine. J&J retained indemnity obligations related to talc litigation, but the corporate restructuring added another layer of separation between the current public entity and the product that caused the harm.
The Texas Two-Step. In 2021, J&J executed a controversial corporate maneuver known as the “Texas two-step” — a divisional merger under Texas law that split its consumer products entity into two companies: one that held the valuable business assets and one (called LTL Management LLC) that held only the talc liability. LTL then filed for Chapter 11 bankruptcy, attempting to force all talc claimants into a bankruptcy trust that would pay pennies on the dollar and permanently shield J&J from talc lawsuits. That bankruptcy was dismissed by a federal judge in 2023 who found the company was not in genuine financial distress. J&J tried again. And again.
Three Failed Bankruptcies. As of the most recent verified record, J&J’s third bankruptcy attempt — through an entity called Red River Talc LLC — was dismissed by the U.S. Bankruptcy Court for the Southern District of Texas on March 31, 2025. The court found vote-solicitation irregularities and impermissible nonconsensual third-party releases. Three times the company tried to wall these cases off inside a bankruptcy it manufactured for that purpose. Three times a court threw it out. The cases are back in the tort system — which is why the Los Angeles trial is happening.
McCrone & Associates. The testing consultant named in the trial testimony as having altered the asbestos test results is a separate defendant with its own exposure. The handwritten note — “Do Not Use This Report: Replaced by Another Version” — is evidence that McCrone knowingly participated in the substitution of a diluted report for the one showing alarming asbestos levels. Under California law, a defendant who knowingly assists in a fraudulent concealment scheme can be held liable for aiding and abetting fraud. McCrone’s role was not passive testing; it was the active suppression of unfavorable scientific findings.
The MDL Context. This Los Angeles trial is not an isolated case. As of June 2026, there were more than 68,000 talc-related actions pending in the federal multidistrict litigation consolidated in the District of New Jersey before Judge Michael A. Shipp — MDL No. 2738, In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation. That number tells you two things: the scale of the harm is enormous, and the evidence being developed in these consolidated proceedings — including the internal documents Kessler testified about — is available to support individual cases across the country.
The Verdict Record. In 2018, a Missouri jury awarded 22 women who claimed J&J talc caused their ovarian cancer $4.69 billion — $4.14 billion of it in punitive damages. The Missouri Court of Appeals reduced the award to approximately $2.12 billion in 2020. The U.S. Supreme Court declined to review the case in June 2021, meaning the reduced $2.1 billion award stands as an affirmed, final judgment. That is not a prediction of what will happen in your case. But it is a public record of what a jury and an appellate court have already done when presented with this evidence.
The Regulatory Framework: Why the FDA Could Not Protect Your Family — and How J&J Allegedly Exploited the Gap
The FDA regulates cosmetic products under the Federal Food, Drug, and Cosmetic Act. But here is the fact that most consumers do not know and that the tobacco-style regulatory history of talc exploitation turns on: historically, the FDA had no pre-market approval authority over cosmetics or cosmetic ingredients, including talc. The agency could not require a company to prove its cosmetic product was safe before selling it. It could not require testing. It could not set limits on contaminants. It relied on industry self-testing and voluntary disclosures — a framework that assumed the company would tell the truth.
Dr. Kessler’s testimony describes what happened when a company did not. J&J and its consultant McCrone altered test results before submitting them to the FDA. J&J convinced the agency to accept an inadequate testing method (the J4-1 test) rather than conducting independent testing. J&J opposed an FDA proposal to test talc for asbestos — not because the testing was unnecessary, but because it might “open up new problem areas.” J&J chemically treated asbestos-contaminated talc without informing the agency. And in 2016, J&J told the FDA that no asbestos-forming structures had ever been found in its talc — a statement a former FDA Commissioner has now called false under oath.
The regulatory void was real. OSHA regulates workplace asbestos exposure, but consumer product exposure falls entirely outside OSHA’s jurisdiction. A worker in a factory has federal asbestos exposure limits. A woman using talc powder in her bathroom has none. The only thing standing between her and a carcinogen in her powder was the company’s honesty — and the evidence says that honesty was systematically dismantled.
The FDA’s cosmetics oversight was significantly expanded by the Modernization of Cosmetics Regulation Act (MoCRA), which introduced facility registration, adverse event reporting, and safety substantiation requirements. But talc-specific asbestos testing requirements remain a subject of ongoing regulatory development. The gap that J&J allegedly exploited for fifty years has not been fully closed.
What Your Case Is Worth: An Honest Evaluation
No lawyer can guarantee a specific outcome or dollar figure. Past results depend on the facts of each case and do not guarantee future outcomes. But we can tell you what the verified analysis of this case type supports — and what drives the numbers up or down.
The case value range for three wrongful deaths from ovarian cancer with surviving statutory beneficiaries, tried in a plaintiff-favorable California venue before a Los Angeles jury, with internal-document evidence of decades-long corporate concealment and a former FDA Commissioner as lead expert witness:
The low end — approximately $25 million — assumes a defense verdict on specific causation (the talc-ovarian cancer link remains scientifically contested) or significant comparative fault arguments that reduce the plaintiff’s recovery. The high end — $300 million or more — reflects a full liability finding with substantial punitive damages driven by the fraud evidence, comparable to mass tort verdicts against pharmaceutical and consumer products corporations in California that have reached nine-figure totals when punitive damages are imposed for document concealment and regulatory deception.
What drives the number:
Compensatory Damages — Economic. Terminal ovarian cancer treatment costs are substantial: surgery (debulking procedures), chemotherapy regimens (platinum-based drugs administered in multiple cycles), hospitalization for complications, palliative care, hospice services, and funeral and burial expenses. If the decedent was employed, lost earnings and lost earning capacity are recoverable — calculated using worklife expectancy tables and projected to present value.
Compensatory Damages — Non-Economic. The survival action captures the decedent’s pre-death pain and suffering: the abdominal pain, the bowel obstruction, the ascites, the cachexia, the fear, the loss of dignity, the knowledge that she was dying. The wrongful death action captures the family’s loss: the financial support she would have provided, the society and companionship she would have shared, the guidance she would have given her children. In California, there is no cap on non-economic damages in product liability cases.
Punitive Damages. This is the central damages amplifier. The trial testimony describing report alteration, a handwritten instruction to suppress unfavorable findings, internal memos opposing FDA testing, chemical treatment of contaminated ore without disclosure, and a 2016 letter a former FDA Commissioner called false provides the clear-and-convincing evidence of fraud and malice that California Civil Code § 3294 requires. The concealment’s duration — from the 1970s through 2016 and beyond — and the number of affected consumers nationwide create a punitive exposure profile that can dramatically exceed the compensatory damages. The $2.1 billion affirmed talc verdict from Missouri — which included a substantial punitive component — is a public data point on what juries have done with this evidence.
Collectibility. Johnson & Johnson maintains the financial depth to satisfy any verdict. The company is one of the largest healthcare corporations in the world. Collectibility is not a limiting factor. What limits recovery is proof — liability, causation, and damages — and the procedural skill to navigate the corporate shell game, the bankruptcy maneuvers, and the defense’s scientific challenges.
The Evidence Clock: What Exists, Who Holds It, and How Fast It Can Disappear
Every piece of evidence in a talc cancer case is on a clock. Some of those clocks are generous. Some are brutal. Knowing the difference is what separates a case that gets filed with a full evidentiary record from one that arrives too late.
Internal J&J Documents. Many of the internal corporate documents from the 1970s onward — the memos, test reports, executive communications, and marginalia that prove knowledge and concealment — have already been produced in existing litigation and are part of the MDL record. But additional internal communications, draft documents, and custodial files may exist in archives, executive files, or collections that have not yet been identified. Targeted discovery motions should be filed promptly. These documents are the foundation of the fraudulent concealment and punitive damages theories. Many are already in evidence in the current Los Angeles trial.
McCrone & Associates Original and Altered Test Reports. The document bearing the handwritten note “Do Not Use This Report: Replaced by Another Version” — and the replacement version that reduced reported tremolite amounts — is the single strongest exhibit for proving fraud and punitive malice. These reports are already in evidence in the current trial. For future claimants, these documents should be demanded through document preservation letters and subpoenas directed to both J&J and McCrone. The original report and the replacement version, placed side by side, tell the story the company did not want the FDA to hear.
FDA Correspondence Files. Federal agency records from the 1970s through 2016 — regulatory submissions, meeting records, correspondence — establish what the FDA was told versus what J&J internally knew. These records are retained under federal records schedules, but FOIA requests face processing backlogs. Requests should be filed immediately for any new claimant. The gap between the FDA’s files and J&J’s internal files is the quantification of the deception.
Dr. Kessler’s Trial Testimony. The transcript of his testimony in this and related talc cases — and any expert reports he prepared — provide uniquely credible expert opinion on regulatory deception and product safety standards. A former FDA Commissioner testifying that a company misled his agency for half a century is not reproducible testimony. Preserving this record through trial transcripts (produced by the court reporter on a standard schedule) supports future claimants and avoids the cost of reproducing equivalent testimony.
Talc Product Samples. Physical product evidence can confirm asbestos contamination through modern analytical methods that exceed the sensitivity of the J4-1 test J&J promoted. Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy with Energy-Dispersive X-Ray Spectroscopy (SEM-EDS) can detect asbestos fibers at concentrations far below the 0.5% threshold the J4-1 test missed. But product samples degrade or are discarded over time. Vintage product containers retained by surviving family members — old bottles of Johnson’s Baby Powder, Shower to Shower containers — should be identified and preserved under chain of custody immediately. If you still have the actual product your loved one used, it is evidence. Do not discard it.
Medical Records and Pathology Specimens. The decedent’s medical records, pathology reports, treatment history, and any tissue specimens document the ovarian cancer diagnosis and progression. Hospital pathology departments retain tissue blocks and slides for years under regulatory requirements, but retention periods vary by institution. Preservation letters should be sent to all treating facilities. The pathology specimens may also be subject to mineralogical analysis — talc and asbestos fibers have been identified in ovarian tissue in published studies, and tissue analysis can provide direct evidence of exposure.
The Deadline Reality. The evidence does not wait for you. Product containers get thrown out during estate cleanouts. Medical records get purged on institutional retention schedules. Witnesses’ memories fade. FOIA requests take months. And the statute of limitations — while potentially extended by the discovery rule — is not infinitely forgiving. The day you call a lawyer is the day the evidence starts being preserved instead of disappearing.
The Defense Playbook: What J&J’s Lawyers Will Do — and How Each Play Is Countered
Johnson & Johnson has been defending talc litigation for years. They have a playbook. Knowing it in advance is not an advantage — it is a necessity.
Play 1: Contest Specific Causation. The defense will argue that ovarian cancer has many causes — genetic factors, reproductive history, hormone use, age — and that the plaintiff cannot prove talc caused this particular cancer. The counter: the plaintiff’s expert team must include a board-certified gynecologic oncologist who can explain the inflammation and particle-translocation pathway, an epidemiologist who can address the association studies, and — critically — a mineralogist who can testify about the asbestos contamination documented in the company’s own internal reports. The asbestos evidence transforms the case from a debatable association study into a known-carcinogen exposure case. If the talc contained asbestos and the company knew it, the “idiopathic cancer” defense loses its force.
Play 2: Attack the Scientific Reliability of the Talc-Ovarian Cancer Link. The defense will file Daubert motions — challenges to the admissibility of the plaintiff’s expert scientific testimony — arguing that the causal link between perineal talc use and ovarian cancer has not been established to a sufficient scientific standard. The counter: the plaintiff must present experts whose methodology is sound, whose opinions are grounded in peer-reviewed literature, and who can withstand cross-examination on the distinction between general causation (talc can cause ovarian cancer) and specific causation (talc caused this plaintiff’s ovarian cancer). The altered McCrone reports and the asbestos contamination evidence are not subject to Daubert challenges — they are documents, not expert opinions. They prove what the company knew, not what the plaintiff’s experts theorize.
Play 3: The Statute of Limitations Trap. The defense will argue that the plaintiff knew or should have known about the talc-ovarian cancer connection years before filing — pointing to media coverage, scientific publications, or the existence of the MDL — and that the discovery rule does not save a claim filed too late. The counter: the discovery rule in California is tied to the plaintiff’s actual knowledge and reasonable diligence, not to the existence of general media coverage. A woman who used talc products for decades and was diagnosed with ovarian cancer may not have known, and may not reasonably have been expected to know, that her cancer was connected to her talc use — especially if the company was simultaneously telling the FDA that no asbestos had been found. The company’s own concealment is the plaintiff’s best answer to the statute of limitations argument: how can the plaintiff be blamed for not discovering a connection the company was actively hiding?
Play 4: The Bankruptcy Shield. J&J has tried three times to use bankruptcy to force all talc claims into a trust and shield itself from individual lawsuits. All three attempts have failed. The counter: the dismissals are matters of public record. But the company may try again. Every talc claimant should be aware that the bankruptcy strategy is not dead — it is dormant. Filing your case in the tort system now, before any fourth bankruptcy attempt, preserves your right to a jury trial.
Play 5: Separating the Brand from the Product. The defense will argue that Kenvue (the consumer health spinoff) is the proper defendant, or that the entity that manufactured the specific product at issue is not the entity being sued, or that the statute of limitations ran against a different corporate entity than the one named in the complaint. The counter: California’s enterprise liability theories and the principle that a parent corporation that controls the operations of its subsidiary can be held liable for the subsidiary’s defective products are the tools to defeat this shell game. Naming every relevant entity — the parent, the consumer subsidiary, the historical manufacturer, the testing consultant — in the initial complaint is how you prevent the defense from winning on a technicality.
Play 6: Minimizing Damages. The defense will argue that the decedent’s suffering was less than claimed, that her earning capacity was limited, that her life expectancy was already reduced by other health factors, and that punitive damages are excessive. The counter: the medical records are the proof of suffering. The chemotherapy logs, the surgical reports, the imaging studies, the hospice notes — these documents speak for themselves. A life-care planner and a forensic economist build the damages number from the ground up, using documented costs and projected care needs. And the punitive damages argument is answered by the company’s own documents: fifty years of concealment is not a mitigating factor. It is the aggravating factor the statute was written to punish.
The Proof Story: How a Talc Cancer Case Is Actually Built
Here is how a case like this is assembled — not in theory, but in practice, from the first phone call through the trial.
Week One. The preservation letter goes out. It is directed to Johnson & Johnson (and its relevant subsidiaries), McCrone & Associates, and every medical facility that treated the decedent. It demands the preservation of all internal documents related to talc testing, asbestos detection, regulatory submissions, and communications with the FDA. It demands the preservation of the decedent’s complete medical record, including pathology slides and tissue blocks. It demands the preservation of any physical product samples. This letter is the first shot — it converts routine document-retention schedules into a legal obligation that, if violated, gives rise to spoliation sanctions.
Weeks Two Through Eight. The records collection begins. Medical records are requested from every treating physician, hospital, chemotherapy infusion center, and hospice provider. The decedent’s product-use history is reconstructed through family interviews: which products did she use, for how long, how frequently, for what purpose. Employment records are obtained to establish lost earnings. FOIA requests are filed with the FDA for all correspondence related to J&J talc products. The MDL document database is accessed through coordination with counsel already involved in the consolidated proceedings — the internal J&J documents produced in the MDL are the same documents that support every individual case.
Months Two Through Six. Expert witnesses are retained. The team typically includes: a board-certified gynecologic oncologist to address specific causation; an epidemiologist to address general causation and the association studies; a mineralogist or analytical chemist to characterize the asbestos fiber types and testing methodology; a forensic document examiner to authenticate the altered McCrone reports; a life-care planner to project the cost of the medical care the decedent received and would have received; and a forensic economist to reduce the lost earnings and future care costs to present value.
Months Six Through Twelve. Discovery proceeds. Written interrogatories are served. Document production is demanded. Depositions are taken — of J&J corporate representatives, of McCrone personnel, of FDA officials involved in the historical talc regulation, of the defense’s retained experts. The altered McCrone reports are authenticated. The 1976 executive memo is authenticated. The 2016 FDA letter is obtained and compared against the internal documents showing what the company actually knew.
Year One and Beyond. The case is set for trial. In Los Angeles County, the trial calendar moves — and the jury pool is one of the most plaintiff-receptive in the United States for corporate fraud and product concealment cases. The evidence is presented. Dr. Kessler’s testimony — preserved in the transcript from the current trial — may be referenced or his expert reports may be used to support the plaintiff’s regulatory-deception theory. The documentary trail is displayed for the jury. The damages are calculated. The verdict is rendered.
This is not a fast process. But the evidence being presented in the Los Angeles courtroom right now — the same documents, the same testimony, the same internal corporate history — is available to support your case. The work has already been done to prove what the company knew and when it knew it. What remains is proving what it did to your family.
What to Do Now: The First Steps for Families Affected by Talc-Related Ovarian Cancer
1. Preserve Physical Evidence. If you still have any talc product containers — Johnson’s Baby Powder, Shower to Shower, or any J&J talc product — that your loved one used, do not throw them away. Store them in a clean, dry place. Photograph the containers, the labels, and any lot numbers or manufacturing codes. These containers are physical evidence that can be tested for asbestos contamination using modern analytical methods that far exceed the sensitivity of the J4-1 test.
2. Obtain Complete Medical Records. Request the complete medical record from every physician, hospital, cancer center, and hospice that treated your loved one. Specifically request pathology reports, surgical operative notes, chemotherapy administration records, imaging studies, and any tissue blocks or slides retained by the pathology department. These records document the injury, the treatment, the suffering, and the damages.
3. Document Product Use History. Write down everything you and other family members remember about your loved one’s talc product use: which brands, which specific products, how frequently, for how many years, for what purpose (feminine hygiene, general body powder, diaper use on children). This history is the exposure evidence that links the product to the injury.
4. Do Not Sign Anything. If you are contacted by anyone representing Johnson & Johnson, its insurers, its claims administrators, or any entity offering a settlement or asking you to sign a release, do not sign anything and do not give a recorded statement. Anything you sign or say can be used against your case. Refer all communications to an attorney.
5. Confirm the Statute of Limitations. Contact an experienced California toxic tort attorney to evaluate the specific timeline of your loved one’s case — the product use period, the diagnosis date, the date you first learned of the possible talc connection, and the date of death if applicable. The discovery rule may preserve a claim you assumed was time-barred, but this must be evaluated by counsel who knows California law.
6. Call Before the Evidence Disappears. The preservation letter — the document that legally freezes the evidence and prevents its destruction — goes out the day you hire a lawyer. Every day before that call is a day the evidence is unprotected.
Frequently Asked Questions
Can I still file a talc ovarian cancer lawsuit if my loved one died years ago?
The answer depends on when she died, when you first learned of the possible connection between her talc use and her ovarian cancer, and the specific rules of California’s discovery rule for toxic exposure cases. California’s statute of limitations for wrongful death is generally two years from the date of death, but the discovery rule — which starts the clock when you discovered or should have discovered both the injury and its causal connection to the product — may extend that deadline in cases where the connection was not previously known. Do not assume it is too late. Confirm the current deadline with experienced counsel immediately.
Does the current Los Angeles trial affect my case?
Yes, in several ways. The evidence being presented in this trial — the internal J&J documents, the altered McCrone reports, the 1976 executive memo, the 2016 FDA letter, Dr. Kessler’s testimony — is being preserved in the trial record and is available to support other cases. The more than 68,000 cases consolidated in the federal MDL have produced a shared document database that individual cases can draw from. And a plaintiff verdict in this Los Angeles trial would increase settlement pressure across the entire talc docket, potentially benefiting cases that are filed or pending at the same time.
What if my loved one used generic or store-brand talc powder, not Johnson & Johnson?
Johnson & Johnson was the dominant manufacturer of talc-based body powder in the United States, and the evidence in this case relates specifically to J&J’s internal testing and regulatory conduct. However, if your loved one used a different brand, the case may involve different defendants and different evidence. The specific product must be identified to determine the correct defendant. Do not assume you have no case because the product was not J&J — talk to an attorney about your specific situation.
How long does a talc cancer lawsuit take?
These are complex cases involving corporate document discovery, multiple expert witnesses, Daubert challenges to scientific evidence, and defendants with enormous resources. A case that goes to trial typically takes one to three years from filing to verdict. Cases that settle may resolve faster, but J&J has historically contested talc-ovarian cancer causation aggressively, and global settlement negotiations have been complicated by the bankruptcy maneuvers. Your attorney can give you a more specific timeline based on the facts of your case and the court’s calendar.
What does it cost to hire a lawyer for a talc cancer case?
Our firm works on contingency. That means we do not charge an hourly fee and we do not bill you for our time. We advance the costs of the case — the filing fees, the expert witness fees, the document production costs, the deposition expenses — and we are paid only if we recover money for you. Our fee is 33.33% of the recovery if the case settles before trial, and 40% if the case goes to trial. If we do not win, you owe us nothing. The consultation is free.
Is the science on talc and ovarian cancer settled?
The association between perineal talc use and ovarian cancer is supported by epidemiological studies, but the defense contests the causal link and argues that ovarian cancer has many causes. The asbestos contamination evidence — documented in J&J’s own internal reports — strengthens the plaintiff’s case significantly because asbestos is a recognized human carcinogen and its presence in the product is not a matter of scientific debate but of corporate documentation. The honest answer is that general causation (talc can cause ovarian cancer) is supported by evidence but contested by the defense, and specific causation (talc caused this plaintiff’s cancer) requires expert testimony tailored to the individual case. The altered McCrone reports and the company’s knowledge of asbestos contamination are the plaintiff’s strongest cards.
What if Johnson & Johnson files for bankruptcy again?
J&J has tried three times to use bankruptcy to shield itself from talc litigation, and all three attempts have been dismissed by federal courts. The company may try again, but each failed attempt weakens the strategy’s viability. If you have a case pending in the tort system when a bankruptcy is filed, your case may be temporarily stayed but it is not automatically dismissed. Filing your case now — before any fourth bankruptcy attempt — preserves your right to a jury trial and your position in the litigation queue.
Can I file a case if my loved one is still alive but has ovarian cancer?
Yes. If your loved one is currently battling ovarian cancer and used talc products for feminine hygiene, she can file a personal injury claim in her own name during her lifetime. This is actually the strongest position to be in because she can testify about her product use, her diagnosis, and her suffering — testimony that a survival action after death cannot fully replace. If she passes away during the litigation, the case can be converted to a wrongful death and survival action. But filing while she is alive preserves the strongest possible evidentiary record.
What is the difference between a wrongful death claim and a survival action in California?
A wrongful death claim is brought by surviving family members (spouse, children, parents, or other statutory beneficiaries) and compensates them for what they lost: the financial support the decedent would have provided, the society and companionship, the guidance and care. A survival action is brought by the decedent’s estate and captures what the decedent lost: her pre-death pain and suffering, her medical expenses, her lost earnings between injury and death. In California, these are separate causes of action with separate beneficiaries and separate damages calculations. A complete case files both.
How do I know if the talc product my loved one used contained asbestos?
The internal J&J documents described in Dr. Kessler’s testimony indicate that the company’s own testing found asbestos contamination in its talc, and that those findings were altered before being reported to the FDA. Modern analytical methods — including Transmission Electron Microscopy (TEM) and Scanning Electron Microscopy with Energy-Dispersive X-Ray Spectroscopy (SEM-EDS) — can detect asbestos fibers at concentrations far below the 0.5% threshold that the J4-1 test missed. If you still have the actual product container, it can be tested. If you do not, the company’s own internal documents — showing what its testing found before the results were altered — are the evidence of what was in the product.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that takes catastrophic injury and wrongful death cases in California, working with local counsel and pro hac vice admission where required. We do not have an office in Los Angeles. We do not claim a California bar admission we do not hold. What we have is 27 years of courtroom experience, a former insurance-defense attorney on our team who knows how the other side prices claims, and the resources and network to coordinate with California counsel and the MDL proceedings to build the strongest possible case for your family.
Ralph Manginello is our Managing Partner. He has been licensed in Texas since November 6, 1998 — 27 years. He is admitted to the U.S. District Court for the Southern District of Texas. He was a journalist before he was a lawyer, which means he reads corporate documents the way a reporter reads a paper trail — looking for the sentence the company did not want to write. He has spent his career in courtrooms, including federal court, and he does not settle cases because they are hard. He settles them when the number is right, and he tries them when it is not.
Lupe Peña is our associate attorney. He was licensed in Texas in 2012 and is also admitted to the U.S. District Court for the Southern District of Texas. Before he joined this firm, he worked inside a national insurance-defense firm — the rooms where adjusters and their software decide how to deny, delay, and devalue claims. He sat in those rooms. He knows how claim valuation software works, how reserves are set in the first 48 hours after an incident, how IME doctors are selected, and how surveillance is deployed. Now he uses that knowledge for injured people. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter.
Hablamos Español. If your family speaks Spanish — if your mother read the warning label (or the absence of one) in Spanish, if your husband is more comfortable explaining what happened in the language he prays in — Lupe conducts the entire consultation in Spanish. No interpreter. No translation gap. The same depth of legal analysis, the same protector voice, in the language your family actually speaks.
The Fee. We work on contingency. The consultation is free. We do not get paid unless we win your case. If we recover money for you, our fee is 33.33% before trial and 40% if the case goes to trial. We advance all case costs — expert witness fees, filing fees, document production costs, deposition expenses — and those costs are repaid from the recovery. If we do not win, you owe us nothing for our time or the costs we advanced.
The First Call. When you call 1-888-ATTY-911, you reach a live person — not an answering service — 24 hours a day, 7 days a week. The first conversation is free and confidential. We will listen to what happened, ask the questions that determine whether you have a case, and tell you honestly whether we are the right firm for you. If we are not, we will tell you that too. What we will not do is pressure you, promise you a result we cannot deliver, or let another day pass without the evidence in your case being preserved.
Past results depend on the facts of each case and do not guarantee future outcomes. The information on this page is legal information, not legal advice. Contacting our firm is free and confidential. Call 1-888-ATTY-911 or reach us through our contact page.
The Bottom Line for Families in Los Angeles
A former Commissioner of the FDA — the person who ran the agency that was supposed to protect your loved one from carcinogens in consumer products — has testified under oath, in a Los Angeles courtroom, that Johnson & Johnson misled his agency for over half a century. He described altered test reports, a handwritten instruction to suppress unfavorable findings, internal memos opposing regulatory testing, chemical treatment of contaminated ore without disclosure, and a 2016 letter to the FDA he called false. Three women are dead. Their families are in that courtroom because they refused to let the story stay buried.
If your family has its own version of this story — a woman who used talc products for years, who trusted a brand that told her its powder was safe, who was diagnosed with ovarian cancer that seemed to come from nowhere — the evidence being presented in this Los Angeles trial may be the evidence that supports your case. But evidence does not preserve itself. Deadlines do not extend themselves. And the company that spent fifty years concealing what it knew is not going to stop defending itself because your family is grieving.
The day you call is the day the preservation letter goes out. The day the evidence stops disappearing. The day the clock starts working for you instead of against you.
Call 1-888-ATTY-911. Free consultation. No fee unless we win. Your family’s story deserves to be heard.